3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Terminated
3
Completed
3
Withdrawn
2
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
11
Immunoglobulin Light-chain Amyloidosis
3
Recurrence
2
Neoplasms, Plasma Cell
2
Waldenstrom Macroglobulinemia
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Interventions
Dexamethasone
18
Cyclophosphamide
16
fludarabine
11
pomalidomide
9
pembrolizumab
9
carfilzomib
9
daratumumab
7
Rituximab
7
Lenalidomide
7
Calcium Dobesilate
7
fludarabine phosphate
6
Cisplatin
6
Bortezomib
6
Gemcitabine
5
venetoclax
4
elotuzumab
4
isatuximab
3
Vincristine
3
Radiotherapy
3
Prednisone
3
Letrozole
3
Etoposide
3
Doxorubicin
3
Cytarabine
3
tisagenlecleucel
2
selinexor
2
ruxolitinib
2
palbociclib
2
ixazomib
2
dexamethasone 21-phosphate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Recurrence
×
ixazomib
×
Clear all
NCT02343042
2026-05-04
STOMP
Karyopharm Therapeutics Inc
Phase 1/2
Active not recruiting
300 enrolled
NCT03651128
2022-12-15
KarMMa-3
Celgene
Phase 3
Active not recruiting
381 enrolled